相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Loredana Cappellacci et al.
CURRENT MEDICINAL CHEMISTRY (2020)
The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma
Claudio Festuccia et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
PDGFR and IGF-1R Inhibitors Induce a G2/M Arrest and Subsequent Cell Death in Human Glioblastoma Cell Lines
Estefania Carrasco-Garcia et al.
CELLS (2018)
Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat
Sofia Rivera et al.
ONCOTARGET (2017)
Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer
Martin Chevrier et al.
BMC CANCER (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells
Florian Handle et al.
MOLECULAR CANCER RESEARCH (2016)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2016)
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
S. J. Thomas et al.
BRITISH JOURNAL OF CANCER (2015)
Suppressor of Cytokine Signaling (SOCS) Genes Are Silenced by DNA Hypermethylation and Histone Deacetylation and Regulate Response to Radiotherapy in Cervical Cancer Cells
Moon-Hong Kim et al.
PLOS ONE (2015)
A Phase III study of radiation therapy (RT) and O6-benzylguanine plus BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001
Deborah T. Blumenthal et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients
Guanghua Li et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression
Gloria Perazzoli et al.
PLOS ONE (2015)
Immunohistochemical expression of glial fibrillary acidic protein and CAM5.2 in glial tumors and their role in differentiating glial tumors from metastatic tumors of central nervous system
Rama Goyal et al.
JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE (2015)
Emerging treatment strategies for glioblastoma multiforme
Steven K. Carlsson et al.
EMBO MOLECULAR MEDICINE (2014)
MGMT Promoter Methylation and Glioblastoma Prognosis: A Systematic Review and Meta-analysis
Yang Chen et al.
ARCHIVES OF MEDICAL RESEARCH (2013)
The Definition of Primary and Secondary Glioblastoma
Hiroko Ohgaki et al.
CLINICAL CANCER RESEARCH (2013)
Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms
Shen-meng Gao et al.
EXPERIMENTAL HEMATOLOGY (2013)
Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells
Hua Xiong et al.
MOLECULAR CARCINOGENESIS (2012)
Current Concepts and Management of Glioblastoma
Matthias Preusser et al.
ANNALS OF NEUROLOGY (2011)
Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
Dagmar Beier et al.
MOLECULAR CANCER (2011)
IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Martin J. van den Bent et al.
CLINICAL CANCER RESEARCH (2010)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
SOCS1 and SOCS3 in the control of CNS immunity
Brandi J. Baker et al.
TRENDS IN IMMUNOLOGY (2009)
Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme
Maurizio Martini et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Analyzing real-time PCR data by the comparative C-T method
Thomas D. Schmittgen et al.
NATURE PROTOCOLS (2008)
Mechanisms of disease: temozolomide and glioblastoma - look to the future
Maciej M. Mrugala et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas
Judith Wm Jeuken et al.
LABORATORY INVESTIGATION (2007)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Reciprocal regulation of SOCS1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme
Hong Zhou et al.
CLINICAL CANCER RESEARCH (2007)
Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals
M. K. Evans et al.
ONCOGENE (2007)
Analysis of gene expression and chemoresistance of CDI33+ cancer stem cells in glioblastoma
Gentao Liu et al.
MOLECULAR CANCER (2006)
Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial
RO Mirimanoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidemiology and etiology of gliomas
H Ohgaki et al.
ACTA NEUROPATHOLOGICA (2005)
The JAK/STAT signaling pathway
JS Rawlings et al.
JOURNAL OF CELL SCIENCE (2004)
分享论文
